KIT and neoplasm: Therefore, blocking the release of mediators with KIT receptor tyrosine kinase inhibitors (TKIs) (for example, imatinib, mastinib) may affect MC function [128,129,130], while blocking the release of mediators with tryptase inhibitors (gabexate mesylate and nafamostat mesylate, both of which are inhibitors of trypsin-like serine proteases) [128,131] can be an important therapeutic treatment for reducing tumor growth [132].